Trial Profile

A Phase 2, Single-arm, Open-label Study to Access Efficacy and Safety of LB54640 in Patients With Obesity Due to POMC, PCSK1, or LEPR Deficiency.

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bivamelagon (Primary)
Indications Obesity
Focus Therapeutic Use
Acronyms ROUTE
Sponsors LG Chem

Most Recent Events

04 Jan 2024 According to Rhythm Pharmaceuticals media release, company announced that it has entered into a global licensing agreement with LG Chem, Under the terms of the agreement, Rhythm will assume sponsorship of this study.
17 Oct 2023 According to LG chem media release, Planned number of patients changed from 4 to 5.
21 Sep 2023 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com